Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sinclair Pharma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 31.80.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Sinclair Pharma. This N/A consensus rating has held steady for over two years.
Sinclair Pharma plc, a specialty pharmaceutical company, engages in the manufacture, commercialization, and sale of dermatological products worldwide. It provides Silhouette Soft, a resorbable poly-L-lactic acid(PLLA)/PLGA suture with bi-directional resorbable cones for skin repositioning and tightening; and Ellansé, which offers dermal fillers. The company also provides Perfectha for wrinkle correction, facial contouring, and volume restoration; and Sculptra designed to stimulate collagen growth. It serves healthcare providers and plastic surgeons. The company was formerly known as Sinclair IS Pharma plc and changed its name to Sinclair Pharma plc in December 2015. Sinclair Pharma plc was founded in 1971 and is headquartered in London, the United Kingdom.